Although effective, a common side effect of DOX therapy is cardiotoxicity, which affects 3% to 26% of patients and often manifests as heart failure (1, 2) . DOX-induced cardiotoxicity is largely dosedependent, thus limiting the use of this agent and optimal oncological treatment (3) . Current guidelines to detect DOX-induced cardiotoxicity are based on the serial assessment of global systolic function.
Generally, the left ventricular (LV) ejection fraction (LVEF) is assessed by nuclear gated blood pool studies or cardiac ultrasound (4) . However, assessment of LVEF is variable and has limited ability to detect early cardiotoxicity, as many patients have histological evidence of cardiotoxicity before decrements in systolic function occur (5) . Importantly, a reduction in LVEF is often an irreversible side effect of DOX therapy, as 45% to 58% do not recover systolic function despite receiving optimal medical therapy (6) . As such, early detection methods of anthracycline-induced cardiotoxicity that precede decrements in LVEF have been proposed (6-10); however, limited or inconsistent data exist regarding the efficacy of these approaches (4) .
The precise mechanisms of DOX-induced cardiotoxicity are not fully elucidated;
although it is well established that DOX induces cardiotoxicity largely through the excessive production of reactive oxygen species (ROS) that lead to direct myocardial apoptosis, contractile abnormalities, inflammation, and vascular injury (11, 12) , and promote deleterious cardiac remodeling by increasing the activity and abundance of matrix metalloproteinases (MMPs) (13, 14) . Some studies report that elevations in circulating biomarkers of oxidative stress (myeloperoxidase) precede clinically significant systolic dysfunction in anthracycline-treated patients (8, 15) . However, the signal-to-noise ratio for cardiac-specific detection of ROS with circulating oxidative stress biomarkers may be low considering that DOX induces oxidative stress in extracardiac organs (e.g., liver, skeletal muscle) (16, 17) , and tumor cells can also produce ROS (18) . Therefore, more targeted detection of ROS activity in the heart may provide a higher sensitivity approach for detecting early cardiotoxicity that often complicates DOX therapy. Recently, a 18 F-labeled analog of dihydroethidium, 18 F-DHMT, was synthesized that permits positron emission tomographic (PET) imaging of superoxide generation in vivo (19, 20) . Initial studies reported an w2-fold short-term increase in 18 The 3D Gaussian filtering with 2-mm full-width-athalf-maximum was applied on the reconstructed images using AMIDE software (version 1.0.4) (22) . In this study, the filtered PET images were only used for volumes of interest (VOIs) definition and image display, whereas the image quantification was performed on the unfiltered PET images. VOIs were drawn on the LV myocardium and within the LV cavity using the Seg3D software (version 2.1.5) (23).
CT images were used to localize the heart and confirm the epicardial surfaces for VOI edge placement.
Standard uptake values (SUVs) were then calculated for the LV myocardium, liver, and LV blood pool.
Differences in blood pool and liver SUV were observed between groups (see later in the text); therefore, the ROS activity ratio was determined as the ratio between LV myocardial SUV and LV blood pool SUV to account for differences in tissue tracer clearance and bioavailability. Boutagy et al. The results of the quantitative analysis of TUNELpositive staining for all rats is shown in Figure 6E .
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E
Unlike the observed progressive histopathologic changes described in the preceding text, cellular apoptosis only trended to increase in DOX-treated rats at 8 weeks compared with time-matched controls rats (p ¼ 0.06) and was significantly increased compared with DOX-treated rats at 4 weeks (p < 0.02) ( Figure 6E ).
DISCUSSION
The major finding from the present study is that 18 Boutagy et al.
